Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Miglustat
11 evidence topics · 12 sources
Guideline recommendation: miglustat for all patients with a confirmed diagnosis
“Miglustat, a substrate reduction therapy, is licensed as a disease‐modifying medicine to treat the neurological manifestations of patients with NPC disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In some patients, miglustat has been shown to attenuate disease progression and improve survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #15: All patients with a confirmed diagnosis of NPC should be considered for miglustat therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strength of recommendation: 1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Level of evidence: B” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expert's opinion: completely agree (44.83%), mostly agree (44.83%), partially agree (10.34%), partially disagree (0.00%), mostly disagree (0.00%), and completely disagree (0.00%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Candidates for miglustat and exclusions in GeneReviews
Approval for Niemann-Pick disease type C outside the United States and off-label use in the United States
“Miglustat, an inhibitor of glucosylceramide synthase, has been approved to treat NPC in other countries; however, its use remains off-label in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat has been shown to ameliorate neurological symptoms and extend survival but does not arrest disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomized controlled trial in participants aged 12 years or older and an uncontrolled pediatric cohort
“Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients aged 12 years or older who had NPC (n=29) were randomly assigned to receive either miglustat 200 mg three times a day (n=20) or standard care (n=9) for 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“12 children younger than 12 years of age were included in an additional cohort; all received miglustat at a dose adjusted for body surface area.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was horizontal saccadic eye movement (HSEM) velocity, based on its correlation with disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, HSEM velocity had improved in patients treated with miglustat versus those receiving standard care; results were significant when patients taking benzodiazepines were excluded (p=0.028).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Children showed an improvement in HSEM velocity of similar size at 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Improvement in swallowing capacity, stable auditory acuity, and a slower deterioration in ambulatory index were also seen in treated patients older than 12 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The safety and tolerability of miglustat 200 mg three times a day in study participants was consistent with previous trials in type I Gaucher disease, where half this dose was used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension in adult and juvenile participants
“All patients completing the randomized trial were allowed to continue treatment in a 12-month, non-controlled open-label extension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean horizontal saccadic eye movement velocity (HSEM-alpha) indicated improvement in the 12-month miglustat group, and stabilization in the 24-month group; swallowing was improved or stable in 86% and in up to 93%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ambulation was stabilized in both the 12- and 24-month groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an exploratory disease stability analysis of prospective data on key parameters of disease progression (HSEM-alpha, swallowing, ambulation and cognition), 13/19 (68%) patients receiving >or= 12 months' miglustat therapy had stable disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among all patients receiving >or= 1 dose of miglustat (n=28), the most frequent adverse events were diarrhoea, weight decrease, flatulence and tremor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Open-label extension in children aged 4 to 12 years
“Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ten children completed 24 months' treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
International NPC Registry: disability during continuous miglustat therapy by age at neurological onset
“In total, 283 patients were enrolled from 28 centers in 13 European countries, Canada and Australia between September 2009 and October 2013; 92 patients received continuous miglustat therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 84 evaluable patients, 9 (11 %) had early-infantile (<2 years), 27 (32 %) had late-infantile (2 to <6 years), 30 (36 %) had juvenile (6 to <15 years) and 18 (21 %) had adolescent/adult (≥15 years) onset of neurological manifestations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Progression of composite disability scores appeared highest among patients with neurological onset during infancy or childhood and lowest in those with adolescent/adult-onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 59/86 evaluable patients (69 %) were categorized as improved/stable and the proportion of improved/stable patients increased with age at neurological onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival with and without miglustat: pooled national cohorts and the NPC Registry
“Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat treatment was associated with a significant reduction in the risk of mortality in neurological onset group patients (adjusted HR [95% CI] 0.510 [0.335, 0.777]; P < .01) (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The effect was consistent across all four age‐at‐neurological‐onset sub‐groups, with a trend that favoured miglustat treatment; all HRs were between 0.364 (late infantile patients) and 0.671 (early infantile patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results were statistically significant for late infantile patients (HR [95% CI] 0.364 [0.165, 0.801]; P < .05); statistical significance was not achieved in the remaining age‐at‐neurological‐onset sub‐groups (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat treatment was associated with a significant reduction in the risk of mortality in diagnosis group patients (HR [95% CI] 0.441 [0.293, 0.664]; P < .001) (Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, this study is the first exploratory analysis conducted in the largest pool of observational data for patients with NP‐C to date, treated in a real‐world setting and with a broad geographical representation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Swallowing outcomes in a single-center cohort with neurological onset before age 15 years
“Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this cohort study of 50 individuals with Niemann-Pick disease, type C1 with neurologic disease onset before age 15 years, miglustat use was associated with stabilized swallowing function and reduced aspiration risk.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat use was associated with decreased odds of worse American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain outcomes in all 3 subsets (overall: odds ratio [OR], 0.09 [95% CI, 0.02-0.36); P < .001; early childhood: OR, 0.17 [95% CI, 0.04-0.67]; P = .01; late childhood: OR, 0.05 [95% CI, 0.01-0.29]; P = .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat use was associated with decreased odds of worse Rosenbek aspiration-penetration scale outcomes in the overall cohort (OR, 0.28 [95% CI, 0.08-0.95]; P = .04) but not in each subgroup (early childhood: OR, 0.27 [95% CI, 0.06-1.22]; P = .09; late childhood: OR, 0.38 [95% CI, 0.06-2.33]; P = .29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infantile onset: French pediatric cohort treated in clinical practice
“Twenty children were enrolled; 19 had NPC1 gene mutations and 1 had NPC2 gene mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight NPC1 patients had the early-infantile, eight had the late-infantile, and three had the juvenile-onset forms of NP-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NP-C disability scale scores indicated either stabilization or improvement of neurological manifestations in 1/8, 6/8, and 1/3 NPC1 patients in these subgroups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mild-to-moderate gastrointestinal disturbances were frequent during the first 3 months of miglustat therapy, but were easily managed with dietary modifications and/or anti-propulsive medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among early-infantile onset patients, a shorter delay between neurological disease onset and miglustat initiation was associated with an initial better therapeutic outcome in one patient, but miglustat did not seem to modify overall disease course in this subgroup.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early infantile onset: French retrospective comparison of treated and untreated patients
“Ten patients were included in the treated group (year of birth: 2006–2012), and 16 patients in the untreated group [born 1987–2005 (n = 15), 2012 (n = 1)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat therapy was started at a median age of 24.5 months (9–29) and median duration was 30 months (11–56).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal adverse events were reported in 7/10 patients on miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients developed loss of psychomotor acquisitions or additional neurological symptoms despite miglustat therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote